Article Text

SP0030 Type I Interferonopathies
  1. L. Rönnblom1
  1. 1Department of Medical Sciences, Uppsala University, Uppsala, Sweden


A number of autoimmune diseases have an increased expression of type I interferon regulated genes in cells from peripheral blood and tissues. This so called interferon signature has been found in patients with SLE, primary Sjögrens syndrome, systemic sclerosis, myositis and a subset of patients with rheumatoid arthritis. The reasons behind the continuous activation of the type I interferon system in patients with these diseases are presence of self-derived inducers of type I interferon production by plasmacytoid dendritic cells (pDCs), lack of proper regulation of cells in the type I interferon system and a genetic predisposition to an enhanced type I interferon response. In fact, a large proportion of the genes predisposing to autoimmunity are involved in the type I interferon signaling pathway, either the production of type I interferon or the response downstream the type I interferon receptor. This has been extensively studied in SLE and among lupus risk genes involved in the production of type I interferon are interferon regulatory factor 5 (IRF5), IRF7 and interleukin-1 receptor associated kinase (IRAK1). SLE susceptibility genes important for the type I interferon response are tyrosine kinase 2 (Tyk2), Signal Transducer and Activator of Transcription 4 (STAT4) and interferon induced with helicase C domain 1 (Ifih1). Several of these genes are in addition risk genes for autoimmune diseases beside SLE. Rare mutations of a number of genes, for instance TREX1 and ACP5, also cause an increased expression of type I interferon stimulated genes and an autoimmune disease resembling SLE. There are several mechanism by which the increased activation of the type I interferon system can contribute to loss of tolerance and an autoimmune disease process. Thus, type I interferon is an immune adjuvant and stimulate cells in both the innate and adaptive immune system, but can also increase the expression of autoantigens. A major challenge in these so called type I interferonopathies is to down regulated the type I interferon system without increasing the risk for severe infections.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.